"This study demonstrates Boston Scientific's commitment to quality and robust post-market surveillance of new leads," said Arjun Sharma, M.D., Vice President, Patient Safety, Boston Scientific CRM. "The data from this post- market study will provide us with a deeper understanding of the lead's performance in real-world practice and will be a welcome addition to the data we collected from the U.S. clinical trial."
Boston Scientific is the only company to offer four fixation designs that provide stability in a variety of venous anatomies, enabling physicians to select the most appropriate lead for their patients. The ACUITY Spiral lead is designed for use with heart failure devices, such as the COGNIS(TM) CRT-D, which received FDA approval earlier this week.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.
Cautionary Statement Regarding Forward Looking Statements
This press release contains forward-looking statements within the
meaning of Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements may be identified by words like "anticipate,"
"expect," "project," "believe," "plan," "estimate," "intend" and similar
words. These forward-looking statements are based on our beliefs,
assumptions and estimates using information available to us at the time and
are not intended to be guarantees of future events or performance. These
forward-looking statements include, among other things, statements
regarding our product performance, regulatory approval of our products, new
product launches, competitive offerings, our growth strategy, and our
market position. If our underlying assumptions turn out to be incorrect, or
if certain r
|SOURCE Boston Scientific Corporation|
Copyright©2008 PR Newswire.
All rights reserved